ApexOnco and other media outlets reported that the FDA has placed a partial clinical hold on the phase III IDeate-Lung02 trial after more patients died from interstitial lung disease than anticipated; ...
The addition of the HER2 tyrosine kinase inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly increased progression-free survival (PFS) compared to a ...
Main Finding: A phase I/II trial supported the safety and efficacy of intermittent administration of VT3989 for the treatment of mesothelioma. Concept: Blocking TEAD autopalmitoylation effectively ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback